About GeneCraft

GeneCraft is a pre-clinical-stage biotech company
dedicated to improving treatment and clinical
outcomes for patients through gene therapy that
harness the innate oncogene defense system.

“Life is a phenomenon of gene expression, and its imbalance causes most of the diseases we know. The most effective tool to correct this imbalance is inevitably ‘gene’. Therefore, gene therapy technology is axiomatically the most effective treatment strategy that can fundamentally treat many diseases that were incurable in the past. We earnestly wish that the gene therapy technology we pursue will let us overcome life-threatening diseases in the near future.”

 Prof. Suk Chul Bae, CEO of GeneCraft 

Suk Chul Bae
Chief Executive Officer/Professor

You Soub Lee 
Chief Scientific
 Officer

Woo jin Kim 
Chief Strategic
Officer/M.D., DDM, PA

Kyoung mi Jung 
Clinical Research
 Officer

Technical Features

GeneCraft is pioneering the field of gene therapy for cancer patients with K-RAS mutation. Our pipeline is designed to unlock the next level of oncology by building on the most recent advances in gene therapy. GeneCraft’s lead program is focused on transforming the treatment paradigm in K-RAS mutated lung cancer by orchestrating gene driven, innate oncogene defense system.


Technology 1.

RX001 is the first-in-class treatment for Pan K-RAS mutated lung cancer.


Technology 2.

RX001 distinguishes abnormal K-RAS mutated cancer cells from normal cells and selectively induces the death of the cancer cells. 


Technology 3.

With its Ubi-AAV Platform, GeneCraft is able to craft gene contents into new gene therapeutics. 

Published
Papers

Cloning, mapping and expression of PEBP2αC, a third gene encoding the mammalian Runt domain

Causal relationship between the loss of RUNX3 expression and gastric cancer

Runx3 Inactivation Is a Crucial Early Event in the Development of Lung Adenocarcinoma

RUNX3 regulates cell cycle-dependent chromatin dynamics by functioning as a pioneer factor of the restriction-point

The RUNX family: developmental regulators in cancer

Read More 

- Tumor suppressor activity of RUNX3 “2004, Oncogene”
- Runx3 is required for the differentiation of lung epithelial cells and suppression of lung cancer “2010, Oncogene”
- How do K-RAS activated cells evade cellular defense mechanisms? “2015, Oncogene”
- Runx3 plays a critical role in restriction-point and defense against cellular transformation “2017, Oncogene”
- Functional relationship between p53 and RUNX proteins”2018, Journal of Molecular Cell Biology”

News 


Notice



Contact

HQ : S19-102, 1, Chungdae-ro, Seowon-gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea (Chungbuk National University) 

Clinical Trial Center :  #649, 6th fl. Keumgang IX Tower, Dongtancheomdan-1ro 27, Hwasung Gyeonggi Provice

Research Exchange Center : 623, Teheran-ro, Gangnam-gu, Seoul, Republic of Korea


GeneCraft

Copyright ⓒ GeneCraft 2022